» Articles » PMID: 29254891

Elevated Cardiac Troponin I, Creatine Kinase and Myoglobin and Their Relationship with Cardiovascular Risk Factors in Patients with Type 2 Diabetes

Overview
Specialty Endocrinology
Date 2017 Dec 20
PMID 29254891
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Elevated cardiac troponin I, Creatine kinase (CK-MB) and Myoglobin levels are observed in the setting of acute myocardial damage. However sub-clinical elevations occur in patients with diabetes mellitus. This study was carried out to determine the relationship between the presence of multiple cardiovascular risk factors and the metabolic syndrome and elevations in cardiac markers in patients with type2 diabetes mellitus.

Subjects And Methods: Consecutive stable out-patients with type2 diabetes mellitus at the University of Port Harcourt Teaching Hospital, Nigeria were recruited. Non-diabetic individuals such as hospital staff and the general public acted as controls. Baseline demographic data collection was done and waist circumference, weight, height and blood pressure were measured. Venous samples were assayed for CTnI, CK-MB and Myoglobin levels using ELISA. Data was analysed using SPSS v 20.

Results: There were 188 DM patients, who were older than the 200 control subjects (56.1 ± 13.1 years and 42.7 ± 5.7 years, p < 0.001). Mean duration of diabetes was 7.1(5.7) years. Hypertension was present in 59%, 84.6% had dyslipidaemia, while 76.1% had metabolic syndrome. All the cardiac markers were significantly higher in DM patients than controls. The presence of hypertension or dyslipidaemia was not significantly associated with the cardiac markers (p > 0.05 for all), however the DM patients with metabolic syndrome had higher levels of CK-MB and myoglobin but not CTnI than those without.

Conclusion: Diabetes mellitus is associated with chronic sub-clinical elevation of cardiac markers and this is more in those with multiple cardiovascular risk factors and/or the metabolic syndrome.

Citing Articles

Prediction Models for Elevated Cardiac Biomarkers from Previous Risk Factors and During the COVID-19 Pandemic in Residents of Trujillo City, Peru.

Caballero-Vidal J, Diaz-Ortega J, Yupari-Azabache I, Castro-Caracholi L, Alva Sevilla J Diagnostics (Basel). 2024; 14(22).

PMID: 39594168 PMC: 11592570. DOI: 10.3390/diagnostics14222503.


The possible protective effect of luteolin on cardiovascular and hepatic changes in metabolic syndrome rat model.

Fikry H, Saleh L, Sadek D, Alkhalek H Cell Tissue Res. 2024; 399(1):27-60.

PMID: 39514020 DOI: 10.1007/s00441-024-03927-1.


The Implication of Elevated Serum Myoglobin Level in Acute Diabetic Complications of Ketoacidosis and Hyperglycemic Hyperosmolar State: A Real-World Study.

Xu C, Wen S, Gong M, Dong M, Yuan Y, Li Y Diabetes Metab Syndr Obes. 2024; 17:2639-2653.

PMID: 38974952 PMC: 11225959. DOI: 10.2147/DMSO.S465311.


Elevated plasma myoglobin level is closely associated with type 2 diabetic kidney disease.

Yang L, Shen Y, Li W, Zha B, Xu W, Ding H J Diabetes. 2023; 16(3):e13508.

PMID: 38036859 PMC: 10925879. DOI: 10.1111/1753-0407.13508.


Exploratory Study Analyzing the Urinary Peptidome of T2DM Patients Suggests Changes in ECM but Also Inflammatory and Metabolic Pathways Following GLP-1R Agonist Treatment.

Lohia S, Siwy J, Mavrogeorgis E, Eder S, Thoni S, Mayer G Int J Mol Sci. 2023; 24(17).

PMID: 37686344 PMC: 10488289. DOI: 10.3390/ijms241713540.